Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc
Astellas Completes Acquisition of Iveric Bio
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ISEE, MDWT, RXDX, UNVR
Iveric Bio stock surges on Astellas Pharma takeover deal
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
Iveric Bio Stock Surges. It's Being Bought by Astellas for $5.9 Billion.
Japan's Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion
These Are the Top 10 Holdings of David Kim
Why Is Iveric Bio (ISEE) Stock Up 25% Today?
IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript
Iveric Bio to Present at Upcoming Investor Conferences
Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio
Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results
These Were The Five Best And Worst Performing Mid-Cap Stocks In September 2022
Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting
IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study
Iveric bio: Further Upside Possible Based On Expanded Opportunities With Zimura
Why Is Iveric Bio (ISEE) Stock Up 56% Today?
Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy
7 Cheap Biotech Stocks to Buy Now
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2022 Results - Earnings Call Transcript
Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results
Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank
Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022
Trial Results Set to Make or Break Small-Cap Pharma Stocks
IVERIC bio: A First Take
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
Iveric Bio to Present at the UBS Global Healthcare Conference 2022
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2022 Results - Earnings Call Transcript
Iveric Bio Reports First Quarter 2022 Operational Highlights and Financial Results
Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks
Learning Lessons From 3 Stocks Flourishing In A Desperate Biotech Bear Market
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2021 Results - Earnings Call Transcript
Iveric Bio Reports Fourth Quarter and Full Year 2021 Operational Highlights and Financial Results
IVERIC bio (ISEE) is on the Move, Here's Why the Trend Could be Sustainable
7 A-Rated Biotechs to Buy for the Long Run
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2021 Results - Earnings Call Transcript
Iveric Bio to Report Third Quarter 2021 Financial Results and Host Conference Call on Tuesday, November 9, 2021
Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field
ISEE Stock: Why It Significantly Increased Yesterday
Iveric Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Here's Why Iveric Bio Stock Is Rocketing Higher Today
ISEE Stock: Why Rival Eye Drug Developer's Disappointment Is a Boon to IVERIC bio
Why IVERIC Bio Shares Are Soaring Today
Why Are Iveric Bio Shares Surging In Premarket Friday?
New Strong Sell Stocks for August 18th